Latest Advances in Lung Cancer Research

New report shows that many of the tumors with low PD-L1 have developed genetic strategies that avoid immunotherapies.

Pre-surgical immunotherapy along with post-surgical immunotherapy significantly improved survival compared to chemotherapy alone for patients with operable non-small cell lung cancer.

The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017.

The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

The researchers hope the findings of ‘ever-changing’ nature of lung cancer could help doctors to tailor treatments for individual patients.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.